Attovia Therapeutics (ATTO) Stock Price, News & Analysis

Company Overview

Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation.

As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.

Key Stats

• Today's Range: $20.02 to $21.60
• 50-Day Range: N/A
• 52-Week Range: $16.15 to $24.32
• Volume: 127,604 shs
• Average Volume: 563,057 shs
• Market Capitalization: $890.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ATTO
• CIK: 2058707
• Web: www.attovia.com
• Phone: (510) 399-5001
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.35 million
• Price / Sales: 659.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,029,000
• Free Float: 42,603,000
• Market Cap: $890.70 million
• Optionable: N/A
• Beta: N/A